Conference sponsors 2021

PLATINUM SPONSOR

Fujifilm is proud to return to Symposium Mammographicum as Platinum Sponsor for the second time and congratulates the organisation as it celebrates 40 years of supporting education, research and innovation in mammography.

We are delighted to welcome Dr Laurie Fajardo who will deliver the Fujifilm Symposium on the topic of Breast Density and Breast Cancer Risk Assessment – Will AI Add Value?  Dr Fajardo is Professor of Radiology at the University of Utah, and has been involved in the development and evaluation of many new breast imaging technologies and therapies.  She has delivered over 200 invited lectures and scientific papers nationally and internationally, and is the author of over 190 scientific papers. Don’t miss this important discussion on Monday 8 February at 3.45pm.

Delegates are also invited to attend the Fujifilm demonstration of the AMULET Innovality.  This highly advanced mammography system can be configured for all clinical mammography applications, including:

  • Dual-mode tomosynthesis – with options to suit every clinical scenario
  • S-view using iterative reconstruction – so you can see every detail more clearly
  • Contrast enhanced mammography – to expand your service
  • Stereotactic and tomo-guided biopsy – with vertical and lateral approaches
  • Breast density module – to support clinical decisions
  • Intelligent AEC – to consistently optimise exposures, even for implants

The AMULET Innovality also offers design and technology which can significantly improve patient comfort. Features including the Fit Sweet compression paddle which wraps to individual breast shape, a fast workflow and ergonomic design all help to ensure the best mammography experience for both patient and mammographer.

Visit our website – https://mammography.fujifilm.eu/

GOLD SPONSOR

At Endomag, we believe everyone deserves a better standard of cancer care. Many of the world’s leading physicians and hospitals use our technologies to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is.

At the heart of the company’s product platform is the Sentimag® localisation system. The Sentimag® system features a probe which works like a metal detector, and when placed near the skin’s surface is used to detect Endomag’s magnetic seed (Magseed®) or liquid tracer (Magtrace®), for tissue localisation and sentinel node biopsy procedures.

Contact us to find out more: www.endomag.com/contact

GOLD SPONSOR 

Hologic® is an innovative medical technology company that enables healthier lives everywhere, every day.

We are also a company that prospers and grows, which is why we’ve been able to expand our offerings to empower even more people and champion women’s health.

What powers our growth across Breast & Skeletal Health, Diagnostics and GYN Surgical is also what differentiates us: the exceptional and clinically proven capacity of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfil by continually challenging ourselves to improve health through better technology, education and market access.

The world leader in mammography, Hologic has expanded its product portfolio significantly through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast cancer diagnosis and care. From digital specimen radiography and stereotactic breast biopsy systems, to breast biopsy markers and surgical guidance systems. Hologic’s comprehensive suite of products is designed to meet the unmet and changing needs of patients and clinicians.

https://hologicbreastsurgery.com/eur/

GOLD SPONSOR 

Siemens Healthineers is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. For more information and latest product line visit www.siemens-healthineers.co.uk.

Twitter: @SiemensHealth

LinkedIn: @Siemens Healthineers # SiemensHealthineers

SILVER SPONSOR 

Volpara Health is a purpose-driven software company on a mission to prevent advanced-stage breast cancer. The Volpara Breast Health Platform includes clinical decision support tools to enable radiologists to make informed and timely decisions about a patient’s need for supplemental imaging and/or genetic testing as part of personalized breast care. Each aspect of this platform is powered by Volpara Science — a set of clinically validated algorithms that use x-ray physics and artificial intelligence to assess breast tissue composition and imaging quality — to personalize patient care.

Twitter: https://twitter.com/Volpara

LinkedIn: https://www.linkedin.com/company/volparasolutions/

Facebook: https://www.facebook.com/VolparaHealth

ONLINE PARTNER 

GE Healthcare is a leading global medical technology and digital solutions innovator. The company has a strong commitment to breast care, and has invested heavily into this technology over the past decades. It is about providing high quality imaging systems enabling clinicians to make faster, more informed decisions leading to positive clinical outcomes.

We all know someone who has been impacted by breast cancer, which is why our dedicated team work tirelessly to improve early detection and support a clear patient care pathway through innovative breast care solutions.

Follow us on FacebookLinkedInTwitter and Insights , or visit our website www.gehealthcare.co.uk for more information

ONLINE PARTNER

ScreenPoint Medical is the leading developer of AI driven image analysis technology which enables the automated reading of 2D and 3D mammograms. With proven accuracy matching that of experienced radiologists, ScreenPoint’s Transpara® system is the most advanced commercially available (CE marked and FDA cleared for 2D and 3D mammography), exploiting Big Data, Deep Learning and the latest advances in Artificial Intelligence to provide an evidence based multi-vendor solution.  Transpara® is used in over 20 countries.  We focus on helping to improve breast cancer survival rates by detecting cancer earlier so that treatment can be more effective and less invasive.  www.screenpoint-medical.com

See our resources here.

ONLINE PARTNER 

It’s UK Medical.

We supply a range of interventional medical devices to the NHS and private healthcare sector. We select proven, clinically effective devices that are cost effective and improve patient outcomes. Everything we do is underpinned by a desire to deliver only the very best customer experience.

We focus on clinical outcomes and work with our customers to achieve the best results. Our focus is 100% people centred. It’s all the little interventions that come together to make a big difference.

For more information please visit our website: ukmedical.com

ONLINE PARTNER

NeoDynamics AB (publ) is a Swedish Med Tech Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative precision biopsy system called NeoNavia.

The NeoNavia system was developed based on research at the Karolinska Institutet in Sweden where patented “Pulse” technology was found to be beneficial in improving outcomes for biopsy procedures, namely, offering clinicians and patients accurate lesion targeting and high tissue yield, aiding correct diagnosis and individualized treatment. NeoNavia is currently being evaluated at leading clinics in UK as part of the COMPULSE study.

We at Neodynamics want to contribute to better diagnostic methods for the millions of women in the world who suffer from breast cancer each year, thereby increasing the chances of survival. Anna Eriksrud, CEO.

www.neodynamics.com